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Activation of T-lymphocytes is an important component of inflammatory and infectious processes, including HIV infection. It is regulated via
the actions of various cell-surface receptors, including CD4 and CXCR4. We examined the roles of CD4 and CXCR4 in the adhesive interaction of
CD4+T-cells with the vascular endothelium. CD4+Jurkat cells were incubated in the presence or absence of anti-CD4 to stimulate CD4, or with
SDF-1 alpha, a cognate ligand of CXCR4. Stimulation of CD4 or CXCR4 each significantly enhanced cell adhesion. We next stimulated the two
receptors together, using gp120, a component of HIV. This enhanced cell adhesion was greater than stimulation of CD4 or CXCR4 individually.
Western blotting revealed that stimulation of CXCR4 by SDF-1 alpha significantly increased the phosphorylation of ERK1/2 in Jurkat cells.
Treatment with anti-CD4 also activated ERK1/2, although to a lesser extent. When the expression of CD4 was reduced by siRNA transfection,
both CD4-dependent adhesion and MAPK activation were diminished. Furthermore, pre-treatment with fluvastatin, significantly attenuated
observed Jurkat cell adhesion. These findings indicate novel mechanisms of CD4+ T-cells recruitment to activated endothelium via CD4 and
CXCR4, which are modulated by statin.
© 2007 Elsevier B.V. All rights reserved.Keywords: Endothelial cells; T-cells; Adhesion Molecules; Inflammation; Statin1. Introduction
Infection of target lymphocytes by human immunodefi-
ciency virus type 1 (HIV-1) requires the expression of
cofactors such as chemokines and their regulators on the
lymphocyte surface, leading to a selective loss of CD4+ T-
cells and fatal immunodeficiency [1–3]. The process of HIV
infection involves the binding of glycoprotein (gp) 120, a
surface component of the viral envelope glycoprotein, to CD4
and CXCR4 receptors expressed on the target cell surface [4].
gp120 first binds to the CD4 receptor, resulting in exposure
of novel binding sites in gp120 by which it binds to the co-⁎ Corresponding author. Life Science and Bioethics Research Center, Tokyo
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doi:10.1016/j.bbadis.2007.01.010receptor CXCR4 [5]. These interactions trigger the fusion and
entry of the viral genome into the host lymphocyte [6].
CXCR4, which was first reported as a receptor for stromal
cell-derived factor (SDF)-1 [7–10], is known to activate
MAPK and divergent intracellular signal pathways [11].
Although the SDF-1 alpha-dependent CXCR4 signal trans-
duction cascade has been studied in T-cells, the biological
consequences of gp120-triggered CXCR4 signal transduction
are not fully understood.
In the present study, we examined the effects of CD4 and
CXCR4 on CD4+ T-cell adhesion to vascular endothelium, and
possible modulation by fluvastatin, a statin drug that inhibits 3-
hydroxyl-3methylglutaryl co-enzymeA (HMG-CoA) reductase.
Statins are used clinically to reduce serum levels of LDL cho-
lesterol as a means to prevent cardiovascular disease [12]. In
addition to their lipid-lowering effect, increasing evidence sup-
ports the anti-inflammatory potential of statins [13]. Our data
Fig. 1. Treatment with SDF-1 alpha, anti-CD4, and gp120 enhances Jurkat T-cell
and lymphocyte adhesion to activated HUVECs. (A) Jurkat T cells were
stimulated with gp120 (2.5 μg/ml) and SDF-1 alpha (80 ng/ml) at 37 °C for
5 min, or anti-CD4 (10 μg/ml) for 40 min at 4 °C, after which the adhesive
interactions with HUVEC monolayers pre-treated with IL-1beta (10 units/ml)
were analyzed using an in vitro flow chamber system at a shear stress of 1 dyn/
cm2. The number of adhering cells was determined as described in Materials and
methods. The graph shown is representative of three experiments. *p<0.05 vs.
controls. (B) CD4+ lymphocytes were prepared from healthy donors as
described in Materials and methods, and adhesion assays were carried out
after gp120, SDF-1 alpha, or anti-CD4 stimulation. #p<0.05 vs. control. The
graph shown is a representative of three experiments.
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stimulated with gp120, suggesting a vascular protective role for
these drugs in HIV-positive patients with atherosclerosis.
2. Materials and methods
2.1. Cell culture
A CD4+ T-cell line (Jurkat cells) was obtained from ATCC (Manassas, VA)
and was cultured in RPMI-1640 supplemented with 10% FCS (LifeFig. 2. Activation of ERK1/2 by SDF-1 alpha, anti-CD4, and gp120. (A) Jurkat Tcells
ml), then subjected to Western blotting using anti-ERK1/2 (bottom bars) and p-ERK
PD98059, 25 μM for 4 h, inhibited SDF-1 alpha-, anti-CD4 and gp120-induced Jurka
LAS-1000CCD camera with ImageGauge 3.4 software. (B) Jurkat cells were treated (
MEK, prior to the adhesion assays. Quantification of p-ERK was normalized again
##p<0.01 vs. anti-CD4(+) PD98059(−). ###p<0.01 vs. gp120(+) PD98059(−). Data
activity in Jurkat T cells. RhoA activity in Jurkat T cells was determined by its transloc
and methods. The cells were treated with gp120 (2.5 μg/ml) and SDF-1 alpha (80 n
PD98059. The density of bands was quantified as described previously. Data ar
Quantification of the RhoA in the membrane fraction was normalized against total celTechnologies Oriental, Inc). Human umbilical vein endothelial cells (HUVECs)
were isolated from normal-term umbilical veins and cultured as described
previously [14]. CD4+T-cells were prepared from human volunteers as follows.
Freshly drawn human blood samples were separated by Histopaque (1.077
density) density-gradient centrifugation to obtain PBMC fractions. CD4+T-
cells were purified from the PBMC fraction through negative selection using a
magnetic cell separation system (Miltenybiotec, MACS CD4+T Cell Isolation
Kit). The purity of CD4+T-cells was determined using a calibrated FACScan
flow cytometer (Becton Dickinson, San Jose, CA). For use in a flow chamber
apparatus, HUVECs were plated on 22-mm fibronectin-coated glass coverslips,
as previously described [15].
2.2. Flow cytometry
Jurkat cells (1×106 cells/ml) were stained with 10 μg/ml of anti-CXCR4
antibody (12G5) or anti-CD4 antibody (13B8.2)[16] for 45 min at 4 °C, then
washed and incubated for an additional 45 min at 4 °C with 10 μg/ml of anti-IgG
FITC secondary antibody (Molecular Probes, Eugene, OR). The cells were
washed and subsequently analyzed using a FACScan apparatus and Cell Quest
software (Becton Dickinson, San Jose, CA).
2.3. Adhesion assay under laminar flow
The protocols of the adhesion assay under flow conditions have been
previously described in detail [17,18]. Briefly, endothelial monolayers on
coverslips were stimulated with IL-1beta (10 units/ml) and cultured for 4 h at
37 °C, then positioned in a flow chamber mounted under an inverted
microscope. Jurkat cells or CD4+T cells were then diluted in the perfusion
medium to 1×105 cells/ml. In some of the experiments, cells were treated with
monomeric gp120 (HIV-1 III B) (2.5 μg/ml) (Immuno Diagnostics, Woburn,
MA) and SDF-1 alpha (80 ng/ml) (PeproTech, Rocky Hill, NJ) at 37 °C for
5 min, or with an anti-CD4 antibody (10 μg/ml) (Beckman Coulter, Fullerton,
CA) for 40 min at 4 °C prior to the assay. PD98059 (Sigma, St. Louis, MO), a
potent inhibitor of MEK (MAP kinase kinase), was used at 25 μM for 4 h at
4 °C prior to the assay. The cells were drawn through the chamber at a
controlled flow rate to generate a calculated wall shear stress of 1.0 dyn/cm2 for
10 min. The entire period of perfusion was recorded on videotape using a digital
video recorder equipped with a time generator. The captured images were
transferred to a personal computer for image analysis to determine the numbers
of adherent cells in 5 to 10 randomly selected x20 microscope fields from each
experiment.
2.4. Western blotting of MAPK
Western blotting was conducted as previously described [19]. In brief, the
cells were cultured in RPMI-1640 containing 0.1% FCS for 48 h, and
thoroughly washed with FCS-free RPMI-1640. Then, the cells were stimulated
with the indicated amount of gp120 (2.5 μg/ml) or SDF-1 alpha (80 ng/ml) for
5 min, or with anti-CD4 (10 μg/ml) for 40 min, after which they were lysed with
a lysis buffer (0.1 M Tris–HCl, 0.15 M NaCl, and 5 mM EDTA, pH 7.4)
containing 1% Triton X-100, 10 μg/ml of leupeptin, 60 U/ml of aprotinin, and
1 mM of PMSF. In some experiments, cells were pretreated with 10 μmol/L of
fluvastatin for 48 h prior to the assay. For Western blot with anti-ERK (K-23)
(Santa Cruz Biotechnology, Santa Cruz, CA) and anti-phospho-ERK (E-4)
(Santa Cruz Biotechnology, Santa Cruz, CA) antibodies, 10 μg of each cellwere treatedwith SDF-1 alpha (80 ng/ml), anti-CD4 (10 μg/ml), or gp120 (2.5 μg/
(top) antibodies, as described in Materials and methods. As pre-treatment with
t cell activation. The density of bands was quantified (bottom bar graph) using an
as described in Fig. 1) in the presence or absence of PD98059, a potent inhibitor of
st total ERK. *p<0.05 vs. controls. #p<0.05 vs. SDF-1 alpha(+) PD98059(−).
are representative of results obtain in three independent experiments. (C) RhoA
ation to the membrane fraction, using a RhoA antibody, as described in Materials
g/ml), or anti-CD4 (10 μg/ml) for 40 min at 4 °C in the presence or absence of
e representative of results obtained in one of two independent experiments.
ls. *p<0.01 vs. anti-CD4(+) PD98059 (−), #p<0.01 vs. gp120 (+) PD98059 (−).
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552 Y. Takano et al. / Biochimica et Biophysica Acta 1772 (2007) 549–555lysate was loaded into each lane. Immunoreactive bands were visualized using a
horseradish peroxidase–conjugated secondary antibody and an enhanced
chemiluminescence system.
2.5. Translocation of RhoA
To examine the translocation of RhoA from the cytosol to the membrane,
membranes and total cell lysates of Jurkat cells (1×106/mL) were prepared as
described previously [18]. An equal amount of protein (10 μg) from each
fraction was subjected to 12.5% SDS-PAGE, and Western blot analysis was
performed using the anti-RhoA monoclonal antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Immunoreactive RhoA was detected with an enhanced
chemiluminescence (ECL) kit (Amersham Pharmacia Biotech).
2.6. Transfection of Jurkat cells with siRNA
The siRNA duplexes against human CD4 cDNA – 5′-GAU CAA GAG
ACU CCU CAG UdGdA-3′ (sense), 5′-ACU GAG GAG UCU CUU GAU
CdTdG-3′ (antisense) [20] – were synthesized, and scrambled siRNA (sciRNA)
of CD4 and LacZ siRNA were used as controls with the following sequences:
scrambled siRNA, 5′-AGU CAG AAG CAC UUC ACA GdAdG-3′ (sense), 5′-
CUG UGA AGU GCU UCU GAC UdGdT-3′ (antisense); LacZ, 5′-CGU ACG
CGGAAUACUUCGAdTdT-3′ (sense), 5′-UCGAAGUAUUCCGCGUAC
GdTdT-3′ (antisense). Nucleofector (Amaxa, Cologne, Germany) was used for
transfection of Jurkat cells following the manufacturer's instructions. In brief,
the cells were resuspended (5×106 cells in 100 μl) in an optimized transfection
solution. Each sample was transfected with 5 μM siRNA using electroporation
with program C-16. After electroporation, cells were immediately transferred to
4.0 ml of complete medium.
2.7. Statistical analysis
Results are presented as means±SD. Data were analyzed using analysis of
variance (ANOVA), with a value of p<0.05 considered significant.Fig. 3. Effect of siCD4 to inhibit CD4-dependent signal in Jurkat T cells. (A)
FACS analysis of Jurkat cells transfected with siRNA against CD4 using an anti-
CD4 mAb. The non-binding isotype control immunoglobulin G mAb (bold line)
is indicated. The data shown are representative of two independent experiments.
(B) siCD4-transfected Jurkat T-cells (siCD4-Jurkat) and control siRNA-
transfected Jurkat T-cells (siLacZ-Jurkat) were treated with SDF-1 alpha, anti-
CD4, and gp120, as described in Materials and methods, after which adhesion
assays were carried out under flow conditions. Data shown are representative of
three similar experiments. *p<0.01 vs. siLacZ-Jurkat anti-CD4. **p<0.05 vs.
siLacZ-Jurkat gp120.3. Results
We first examined whether activation of CXCR4 and CD4
would induce Jurkat T-cell adhesion to vascular endothelium.
Jurkat T-cells were incubated in the presence of SDF-1 alpha
(80 ng/ml) at 37 °C for 5 min, or anti-CD4 mAb (10 μg/ml) for
40 min, after which adhesion assays were carried out under flow
conditions. As shown in Fig. 1A, treatment with SDF-1 alpha
and anti-CD4 each increased Jurkat T-cell adhesion to activated
HUVECs (SDF-1 alpha, p<0.05 vs. control; anti-CD4, p<0.05
vs. control). Interestingly, treatment with gp120, expected to
activate both CXCR4 and CD4, induced a much higher level of
adhesion to HUVECs [gp120 (−), 3.0±0.76; gp120 (+), 11.9±
1.86; p<0.05]. Under static conditions, Jurkat cell adhesion was
maximal at 2.5 μg/ml of gp120 (data not shown). The surface
expression of CXCR4was not affected by SDF-1 alpha or gp120
in Jurkat cells (data not shown). To explore the responsible
adhesion molecules on Jurkat T-cell adhesion, a fluorescent
immunoassay was carried out using anti-LFA-1 and VLA-4
antibodies. The expression levels of LFA-1 and VLA-4 on their
surface were not significantly changed before and after treatment
with SDF-1 alpha, anti-CD4, and gp120 (data not shown).
Adhesion assays were also carried out using freshly isolated
CD4+lymphocytes. As shown in Fig. 1B, SDF-1 alpha, anti-
CD4, and gp120 induced similar levels of CD4+lymphocyte
adhesion. To investigate intracellular machinery, we examinedthe phosphorylation ofMAPK after CXCR4 or CD4 stimulation.
We found that phosphorylation of ERK1/2 was enhanced by
treatment with SDF-1 alpha and gp120, and to a lesser extent
with anti-CD4 (Fig. 2A). Pre-treatment with PD98059, a potent
inhibitor of MEK, reduced observed phosphorylation of ERK1/
2. PD98059 also inhibited SDF-1 alpha- [SDF-1(+), 7.3±0.68
cells/HPF; SDF-1(+)PD98059(+), 3.1±1.12; p<0.05], anti-
CD4-[anti-CD4(+), 6.7±0.81 cells/HPF; anti-CD4(+)PD98059
(+), 4.1±0.67; p<0.01] and gp120-induced [gp120(+), 11.4±
1.12 cells/HPF; gp120(+)PD98059(+), 7.1±0.87; p<0.01]
Jurkat cell adhesion (Fig. 2B). Further, the involvement of
RhoA, a member of the small GTP-binding protein family,
was also examined because RhoA plays a role in cell motility
and adhesion in various cell types [21–23]. As shown in Fig.
2C, membrane translocation of RhoA was enhanced following
treatment with SDF-1 alpha, anti-CD4, and gp120. In the
presence of PD98059, these activations of RhoA were
reduced.
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CXCR4-dependent pathways, siRNA against CD4 (siCD4) was
transfected into Jurkat cells to inhibit CD4-dependent signaling.
Transfection of siCD4 effectively reduced CD4 expression (Fig.
3A) and both anti-CD4-induced [siLacZ(+), 5.3±1.41 cells/
HPF; siCD4(+), 4.0±1.15; p<0.05] gp120-induced [siLacZ(+),
9.2±1.4 cells/HPF; siCD4(+), 6.8±1.23; p<0.01] cell adhesion
were attenuated (Fig. 3B).Fig. 4. Potential effects of fluvastatin in SDF-1 alpha- and gp120-induced Jurkat T-
fluvastatin (10 μM) for 48 h, followed by stimulation with SDF-1 alpha (80 ng/ml,
Adhesion assays were carried out as described in Materials and methods. Data show
ERK1/2 after fluvastatin treatment was examined by Western blot, using the conditio
(−), **p<0.01 vs. anti-CD4 (+) Fluvastatin (−), ***p<0.01 vs. gp120 (+) FluvastaIt is reported by us and others, a pharmacological inhibitor of
HMG-CoA reductase, statin reduces monocyte adhesion to
HUVEC. We thus examined the effect of statin in Jurkat cell
adhesion. Jurkat cells were incubated in the presence of 10 μM
of fluvastatin for 48 h. In preliminary experiments, the viability
of Jurkat cells in the presence of 10 μM of fluvastatin was 90%
(data were not shown). As shown in Fig. 4A–C, pre-treatment
with fluvastatin significantly inhibited adhesion induced bycell adhesion. (A–C) Jurkat cells were incubated in the presence or absence of
A) and gp120 (2.5 μg/ml, C) for 5 min or anti-CD4 (10 μg/ml, B) for 40 min.
n are representative of three separate experiments. (D) The phosphorylation of
ns described in Materials and methods. *p<0.01 vs. SDF-1 alpha (+) Fluvastatin
tin (−).
Fig. 5. Schematic representation of cell adhesion and ERK1/2 activation in CD4+
T cells induced by gp120 and SDF-1 alpha.
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vastatin did not change the baseline level of adhesion. We then
determined the phosphorylation of ERK following incubation
with fluvastatin. As demonstrated in Fig. 4D, fluvastatin effec-
tively inhibited ERK phosphorylation.
4. Discussion
During the process of HIV infection, the interaction of gp120
with chemokine receptors, including CXCR4, is a critical step
that permits fusion of the viral membrane with the cellular
membrane and subsequent penetration of viral genetic material
into the cytoplasm [24]. Chemokine receptors play key roles in
leukocyte recruitment to the vascular endothelium. We therefore
examined the effects of gp120 in CD4+ Jurkat T –cells, and
found that it significantly induced an adhesive interaction with
vascular endothelium (HUVEC cells). Stimulation of anti-CD4
or CXCR4 individually also induced CD4+Jurkat cell adhesion
to vascular endothelium, although to a lesser extent than gp120.
These findings may indicate an inflammatory potential of gp120
in T-cell activation.
The HIV envelope protein gp120 activates a variety of
signaling pathways in lymphocytes, including the ERK path-
way. As previously reported [25,26], SDF-1 alpha induces the
phosphorylation of MAP kinase via CXCR4 in both Jurkat T
cells and CD4+T cells. Here, we have further demonstrated that
ERK phosphorylation plays an important role in the enhanced
adhesion of Jurkat T cells meditated by SDF-1 alpha, anti-CD4,
and gp120. ERK1/2 phosphorylation is required for integrin
activation in many cell types. For example, platelet activation
factor (PAF) has been shown to induce CD11b/CD18 expression
via ERK-dependent pathways in neutrophils. In another report,
MCP-1-induced adhesion of monocytes was reduced by PD9
8059 treatment [27]. Therefore, we think that ERK1/2 activation
could be one of primary mechanisms controlling cell adhesion.
A recent study by Brainard et al. using human Tcells reported
that CD4-dependent signal transduction was more significant
than an SDF-1 alpha-dependent pathway [28]. In the present
study, however, ERK1/2 activation upon CD4 stimulation was
almost comparable to that upon CXCR4 stimulation (Fig. 2A).
This discrepancy may be explained, at least in part, by the
speculation that gp120 prepared from different HIV strains
activates different signal pathways, or because different T-cell
populations may possess different signal pathways. As attenua-
tion of the CD4-dependent signal by siRNA did not affect SDF-1
alpha-dependent adhesion, we conclude that the expression of
CD4 is not necessary for CXCR4 to induce ERK1/2 phosphor-
ylation. Whether the CXCR4-dependent signaling pathway is
identical to or distinct from that of CD4 should be clarified in
future. Previous studies claimed that SDF-1 alpha induces
internalization of CXCR4 in lymphocytes[29, 30], which was
not observed in our condition. Considering the distinct sustained
activation of CXCR4 by gp120 in neurons [31], different T-cell
populations may possess different regulatory mechanisms of
CXCR4 expression.
We also identified an involvement of RhoA GTPase follo-
wing activation of ERK1/2 in SDF-1 alpha- and gp120-dependent Jurkat cell activation (Fig. 2C). This suggests a
sequential activation of ERK1/2 and RhoA by SDF-1 alpha and
gp120 (Fig. 5).
In the present study, we showed the potential activation of T-
lymphocytes by gp120, which may therefore play a role in
inflammation in HIV-positive subjects. Recent therapeutic
advances in HIV infection have increased the number of HIV
patients with chronic pathological conditions, such as athero-
sclerosis due to hyperlipidemia caused by anti-HIVmedications.
Our current study points to a unique molecular mechanism of
inflammation induced by HIV envelope protein, gp120, and its
modulation by statins. Though our data did not support their
effects on transmigration of T cells, an anti-inflammatory role of
statin could be demonstrated in HIV patients in future.
In summary, our findings indicate a role for gp120 in the
induction of adhesion of Jurkat cells in a CXCR4- and CD4-
dependent manner. We also found a protective role for
fluvastatin in the modulation of Jurkat cell adhesion to activated
vascular endothelium induced by SDF-1 alpha and gp120.
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